Efficient production of myo-inositol in Escherichia coli through metabolic engineering.

Publisher: BioMed Central Country of Publication: England NLM ID: 101139812 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2859 (Electronic) Linking ISSN: 14752859 NLM ISO Abbreviation: Microb Cell Fact Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Escherichia coli*/genetics ; Escherichia coli*/metabolism ; Metabolic Engineering*; Inositol/*biosynthesis; Bacterial Proteins/metabolism ; Industrial Microbiology

Background: The biosynthesis of high value-added compounds using metabolically engineered strains has received wide attention in recent years. Myo-inositol (inositol), an important compound in the pharmaceutics, cosmetics and food industries, is usually produced from phytate via a harsh set of chemical reactions. Recombinant Escherichia coli strains have been constructed by metabolic engineering strategies to produce inositol, but with a low yield. The proper distribution of carbon flux between cell growth and inositol production is a major challenge for constructing an efficient inositol-synthesis pathway in bacteria. Construction of metabolically engineered E. coli strains with high stoichiometric yield of inositol is desirable.
Results: In the present study, we designed an inositol-synthesis pathway from glucose with a theoretical stoichiometric yield of 1 mol inositol/mol glucose. Recombinant E. coli strains with high stoichiometric yield (> 0.7 mol inositol/mol glucose) were obtained. Inositol was successfully biosynthesized after introducing two crucial enzymes: inositol-3-phosphate synthase (IPS) from Trypanosoma brucei, and inositol monophosphatase (IMP) from E. coli. Based on starting strains E. coli BW25113 (wild-type) and SG104 (ΔptsG::glk, ΔgalR::zglf, ΔpoxB::acs), a series of engineered strains for inositol production was constructed by deleting the key genes pgi, pfkA and pykF. Plasmid-based expression systems for IPS and IMP were optimized, and expression of the gene zwf was regulated to enhance the stoichiometric yield of inositol. The highest stoichiometric yield (0.96 mol inositol/mol glucose) was achieved from recombinant strain R15 (SG104, Δpgi, Δpgm, and RBSL5-zwf). Strain R04 (SG104 and Δpgi) reached high-density in a 1-L fermenter when using glucose and glycerol as a mixed carbon source. In scaled-up fed-batch bioconversion in situ using strain R04, 0.82 mol inositol/mol glucose was produced within 23 h, corresponding to a titer of 106.3 g/L (590.5 mM) inositol.
Conclusions: The biosynthesis of inositol from glucose in recombinant E. coli was optimized by metabolic engineering strategies. The metabolically engineered E. coli strains represent a promising method for future inositol production. This study provides an essential reference to obtain a suitable distribution of carbon flux between glycolysis and inositol synthesis.

Biotechnol Bioeng. 2017 Aug;114(8):1855-1864. (PMID: 28409846)
Fish Shellfish Immunol. 2018 May;76:333-346. (PMID: 29544771)
Metab Eng. 2012 May;14(3):233-41. (PMID: 22629571)
Obstet Gynecol Int. 2014;2014:141020. (PMID: 24876842)
Biotechnol Bioeng. 2003 Sep 20;83(6):687-94. (PMID: 12889033)
J Biol Chem. 1960 Sep;235:2522-8. (PMID: 13827770)
Eur J Biochem. 1973 Sep 21;38(1):103-10. (PMID: 4774118)
Lancet. 1978 Dec 16;2(8103):1282-4. (PMID: 82784)
Arch Gynecol Obstet. 2015 May;291(5):1181-6. (PMID: 25416201)
Enzyme Microb Technol. 2019 Aug;127:70-74. (PMID: 31088620)
Curr Protoc Mol Biol. 2007 Jul;Chapter 1:Unit 1.17. (PMID: 18265391)
Microb Cell Fact. 2017 Apr 21;16(1):67. (PMID: 28431560)
Metab Eng. 2015 Mar;28:104-113. (PMID: 25542851)
Metabolism. 1979 Apr;28(4 Suppl 1):477-83. (PMID: 262775)
Mol Syst Biol. 2006;2:2006.0008. (PMID: 16738554)
Nat Biotechnol. 2015 Oct;33(10):1061-72. (PMID: 26448090)
J Bacteriol. 2004 Oct;186(20):6915-27. (PMID: 15466045)
Nature. 2008 Feb 7;451(7179):652-7. (PMID: 18256660)
Mol Syst Biol. 2009;5:335. (PMID: 20029369)
Bioengineered. 2014 Sep-Oct;5(5):331-4. (PMID: 25482235)
Enzyme Microb Technol. 2016 Sep;91:8-16. (PMID: 27444324)
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5. (PMID: 10829079)
Appl Environ Microbiol. 2017 Aug 1;83(16):. (PMID: 28600316)
Enzyme Microb Technol. 2018 May;112:1-5. (PMID: 29499774)
Appl Environ Microbiol. 2015 Apr;81(7):2506-14. (PMID: 25636838)
Nucleic Acids Res. 2011 Jan;39(Database issue):D583-90. (PMID: 21097882)
Plant Cell. 2011 Apr;23(4):1352-72. (PMID: 21505066)
Br J Nutr. 2018 Jun 3;:1-16. (PMID: 29859544)
Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151-9. (PMID: 15206484)
Proc Natl Acad Sci U S A. 1964 Nov;52:1207-13. (PMID: 14231443)
Altern Med Rev. 1998 Dec;3(6):432-47. (PMID: 9855568)
Fish Shellfish Immunol. 2017 Aug;67:475-492. (PMID: 28610850)
Rev Endocr Metab Disord. 2016 Dec;17(4):471-484. (PMID: 27315814)
Trends Biotechnol. 2016 Aug;34(8):652-664. (PMID: 26996613)
Adv Nutr Res. 1982;4:107-41. (PMID: 6278902)
Microb Cell Fact. 2019 Aug 6;18(1):130. (PMID: 31387584)
Biochem Med Metab Biol. 1992 Aug;48(1):46-55. (PMID: 1388035)
Nat Methods. 2009 May;6(5):343-5. (PMID: 19363495)
J Ind Microbiol Biotechnol. 2017 May;44(4-5):773-784. (PMID: 27837351)

31670051 National Natural Science Foundation of China

Keywords: Bioconversion; Escherichia coli; High density fermentation; High stoichiometric yield; Metabolic engineering; Myo-inositol

0 (Bacterial Proteins)
4L6452S749 (Inositol)

Date Created: 20200526 Date Completed: 20210128 Latest Revision: 20210128

20250114

PMC7247202

10.1186/s12934-020-01366-5

32448266